{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:43:20Z","timestamp":1790642600786,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,7,20]],"date-time":"2007-07-20T00:00:00Z","timestamp":1184889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s10792-007-9122-1","type":"journal-article","created":{"date-parts":[[2007,7,18]],"date-time":"2007-07-18T19:07:37Z","timestamp":1184785657000},"page":"101-109","source":"Crossref","is-referenced-by-count":34,"title":["Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG\/EOG) tests in two subgroups of patients"],"prefix":"10.1007","volume":"28","author":[{"given":"Focke","family":"Ziemssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"L\u00fcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Messias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olcay","family":"Tatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhart","family":"Zrenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl U.","family":"Bartz-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Tuebingen Bevacizumab Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,7,20]]},"reference":[{"key":"9122_CR1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irnotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"9122_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00417-006-0466-4","volume":"245","author":"R Lazic","year":"2007","unstructured":"Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68\u201373","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9122_CR3","doi-asserted-by":"crossref","unstructured":"Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal teleangiectasis. Graefes Arch Clin Exp Ophthalmol. E-Pub","DOI":"10.1007\/s00417-006-0468-2"},{"key":"9122_CR4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/bjo.2006.102293","volume":"90","author":"S Michels","year":"2006","unstructured":"Michels S (2006) Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 90:1333\u20131334","journal-title":"Br J Ophthalmol"},{"key":"9122_CR5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344\u20131349","journal-title":"Br J Ophthalmol"},{"key":"9122_CR6","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.2174\/138161206777698738","volume":"12","author":"P Lazarovici","year":"2006","unstructured":"Lazarovici P, Marcinkiewicz C, Lelkes PI (2006) Cross talk between the cardiovascular and nervous system: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF). Curr Pharm Des 12:2609\u20132622","journal-title":"Curr Pharm Des"},{"key":"9122_CR7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainres.2006.07.060","volume":"18","author":"Y Wang","year":"2006","unstructured":"Wang Y, Galvan V, Gorostiza O, Ataie M, Jin K, Greenberg DA (2006) Vascular endothelial growth factor improves recovery of sensimotoric and cognitive deficits after focal cerebral ischemia in rat. Brain Res 18:186\u2013193","journal-title":"Brain Res"},{"key":"9122_CR8","first-page":"853","volume":"12","author":"P Lanthony","year":"1986","unstructured":"Lanthony P (1986) Evaluation du Panel D15 d\u00e9satur\u00e9. J Fr Ophthalmol 12:853\u2013847","journal-title":"J Fr Ophthalmol"},{"key":"9122_CR9","first-page":"50","volume":"29","author":"AJ Vingrys","year":"1988","unstructured":"Vingrys AJ, King-Smith PEA (1988) A quantitative scoring technique for panel tests of color vision. Inv Ophthalmol Vis Sci 29:50\u201363","journal-title":"Inv Ophthalmol Vis Sci"},{"key":"9122_CR10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2005.07.041","volume":"141","author":"TJ McCulley","year":"2006","unstructured":"McCulley TJ, Golnik KC, Lam BL, Feuer WJ (2006) The effect of decreased visual acuity on clinical color vision testing. Am J Ophthalmol 141:194\u2013196","journal-title":"Am J Ophthalmol"},{"key":"9122_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10633-006-9030-0","volume":"113","author":"M Brown","year":"2006","unstructured":"Brown M, Marmor M, Vaegan, Zrenner E, Brigell M, Bach M (2006) ISCEV standard for clinical electro-oculography (EOG) 2006. Doc Ophthalmol 113:205\u2013212","journal-title":"Doc Ophthalmol"},{"key":"9122_CR12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1113\/jphysiol.1966.sp008001","volume":"185","author":"KI Naka","year":"1966","unstructured":"Naka KI, Rushton WAH (1966) S-potentials from colour units in the retina of the fish (cyprinidae). J Physiol 185:536\u2013555","journal-title":"J Physiol"},{"key":"9122_CR13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1475-1313.2004.00266.x","volume":"25","author":"N Langellan","year":"2005","unstructured":"Langellan N, Wouters B, Moll AC, de Boer MR, van Rens GHMB (2005) Intra- and interrater agreement and reliability of the functional field score. Ophthalmic Physiol Opt 25:136\u2013142","journal-title":"Ophthalmic Physiol Opt"},{"key":"9122_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1364\/JOSA.53.000185","volume":"53","author":"G Verriest","year":"1963","unstructured":"Verriest G (1963) Further studies on acquired deficiency of color discrimination. J Opt Soc Am 53:185\u2013193","journal-title":"J Opt Soc Am"},{"key":"9122_CR15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archopht.121.11.1557","volume":"121","author":"M Ladewig","year":"2003","unstructured":"Ladewig M, Kraus H, Foerster MH, Kellner U (2003) Cone dysfunction in patiens with late-onset cone dystrophy and age-related macular degeneration. Arch Ophthalmol 121:1557\u20131561","journal-title":"Arch Ophthalmol"},{"key":"9122_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000267283","volume":"25","author":"M Anastai","year":"1993","unstructured":"Anastai M, Brai M, Lauricella M, Geracitano R (1993) Methodological aspects of the application of the Naka\u2013Rushton equation to clinical electroretinogram. Ophthalmic Res 25:145\u2013156","journal-title":"Ophthalmic Res"},{"key":"9122_CR17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF01214651","volume":"91","author":"M H\u00e9bert","year":"1996","unstructured":"H\u00e9bert M, Lachapelle P, Dumont M (1996) Reproducibility of electroretinogramms with DTL electrodes. Doc Ophthalmol 91:333\u2013342","journal-title":"Doc Ophthalmol"},{"issue":"12","key":"9122_CR18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s004170050331","volume":"237","author":"P Walter","year":"1999","unstructured":"Walter P, Widder RA, Luke C, Koenigsfeld P, Brunner R (1999) Electrophysiological abnormalities in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 237(12):962\u2013968","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9122_CR19","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/bjo.2006.094995","volume":"90","author":"M Luke","year":"2006","unstructured":"Luke M, Warga M, Ziemssen F et al (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90:1178\u20131182","journal-title":"Br J Ophthalmol"},{"key":"9122_CR20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"},{"key":"9122_CR21","doi-asserted-by":"crossref","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257\u2013261; Graefe's Arch Clin Exp Ophthalmol 237:962\u2013968","DOI":"10.1097\/00006982-200603000-00001"},{"key":"9122_CR22","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.iae.0000230717.85319.f5","volume":"26","author":"L Feiner","year":"2006","unstructured":"Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26:882\u2013888","journal-title":"Retina"},{"key":"9122_CR23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00006982-200603000-00003","volume":"26","author":"RK Maturi","year":"2006","unstructured":"Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after bevacizumab (Avastin) treatment. Retina 26:270\u2013274","journal-title":"Retina"},{"key":"9122_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10633-006-9036-7","volume":"114","author":"MM Moschos","year":"2007","unstructured":"Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study: multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114:37\u201344","journal-title":"Doc Ophthalmol"},{"key":"9122_CR25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/02713680490516198","volume":"29","author":"B Feigl","year":"2003","unstructured":"Feigl B, Brown B, Lovie-Kitchin J, Swann P (2003) Cone-mediated multifocal electroretinogramm in early age-related maculopathy and its relationships with subjective macular function tests. Curr Eye Res 29:327\u2013336","journal-title":"Curr Eye Res"},{"key":"9122_CR26","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1167\/iovs.02-0769","volume":"44","author":"JA Phipps","year":"2003","unstructured":"Phipps JA, Guymer RH, Vingrys AJ (2003) Loss of cone function in age-related maculopathy. Invest Ophthalmol Vis Sci 44:2277\u20132283","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9122_CR27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/bjo.2003.033480","volume":"88","author":"GB Arden","year":"2004","unstructured":"Arden GB, Wolf JE (2004) Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol 88:1180\u20131185","journal-title":"Br J Ophthalmol"},{"key":"9122_CR28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0039-6257(00)00125-9","volume":"45","author":"HPN Scholl","year":"2000","unstructured":"Scholl HPN, Zrenner E (2000) Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 45:29\u201347","journal-title":"Surv Ophthalmol"},{"key":"9122_CR29","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2006.095190","volume":"90","author":"MS Spitzer","year":"2006","unstructured":"Spitzer MS, Wallenfels-Thilo B, Sierra A et al (2006) Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90:1316\u20131321","journal-title":"Br J Ophthalmol"},{"key":"9122_CR30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.iae.0000222547.35820.52","volume":"26","author":"S Luthra","year":"2006","unstructured":"Luthra S, Narayanan R, Marques LE et al (2006) Evaluation of in\u00a0vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26:512\u2013518","journal-title":"Retina"},{"key":"9122_CR31","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1167\/iovs.06-1171","volume":"48","author":"P Heiduschka","year":"2007","unstructured":"Heiduschka P, Fietz H, Hofmeister S et al (2007) Penetration of bevacizumab through the retina after intravitreal injection in monkey. Invest Opht Vis Res 48:2814\u20132823","journal-title":"Invest Opht Vis Res"},{"key":"9122_CR32","first-page":"31","volume":"43","author":"K Gora-Kupilas","year":"2005","unstructured":"Gora-Kupilas K, Josko J (2005) The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol 43:31\u201339","journal-title":"Folia Neuropathol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-007-9122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-007-9122-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-007-9122-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T20:24:10Z","timestamp":1559247850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-007-9122-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,20]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["9122"],"URL":"https:\/\/doi.org\/10.1007\/s10792-007-9122-1","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,20]]}}}